Biotech and Pharmaceuticals Biotechnology

More

  • ImClone's Waksal plans IPO

    CNBC's Meg Tirrell reports Sam Waksal is back in the biotechnology industry.

  • Tax crackdown impact on pharma deals

    Discussing how the Treasury Department's new rules to end tax inversions could impact the pharma deals, with Michael Faerm, Wells Fargo Securities.

  • 3 Biotech picks: Gilead, Biogen & Celgene

    Breaking down the hottest stocks in biotech now, with John Schroer, Allianz Global Investors.

  • Race for cholesterol drugs

    A new class of drugs which aim to lower levels of LDL are being pursued by multiple pharma companies and it could be a $10 billion market. Leonard Schleifer, Regeneron CEO, discusses what is known about bad cholesterol, and competition in the space.

  • Why US biotech stocks are back in favor

    While biotechnology shares are not cheap, they are nowhere near "bubble-like" valuations, says Bill Stone, Chief Investment Strategist at PNC Asset Management Group.

  • Roche's blockbuster pharma deal

    CNBC's Meg Tirrell breaks down the mega deal between Swiss pharmaceutical firm Roche and InterMune for $8.3 billion.

  • What Roche gets from InterMune

    Switzerland's Roche is buying InterMune for $8.3 billion. CNBC's Meg Tirrell reports InterMune's Esbriet drug could draw more than $1 billion in annual revenue.

  • Drug giant Roche is buying biotech firm InterMune for $8.3 billion. CNBC's Jim Cramer discusses the lifesaving drug behind the wave of M&A deals.

  • Big change for pain drugs

    CNBC's Meg Tirrell reports the Drug Enforcement Administration is changing the rules around pain drugs like Vicodin. The drugs will be deemed "schedule 2 substances," versus the less restrictive "schedule 3."

  • Hot biotech drugs

    CNBC's Meg Tirrell reports which biotech drug developments investors are excited about.

  • Fighting obesity with Rxs

    Zafgen CEO Tom Hughes discusses the company's dedication to tackle obesity, with CNBC's Meg Tirrell. Hughes says the new drug works to impact the way the body handles fat.

  • Red hot biotech stocks

    CNBC's Morgan Brennan runs through today's big biotech movers.

  • Time to buy biotech?

    Barbara Ryan, FTI Consulting, discusses the tremendous amount of innovation within in the biotech sector and why the segment is attractive.

  • Biotechs race for Ebola cure

    CNBC's Meg Tirrell looks at companies in the early stages of Ebola drug and vaccine trials.

  • Merck & Pfizer beat the Street

    CNBC's Meg Tirrell reports both Merck and Pfizer beat earnings expectations amid patent expirations.

  • What's coming in biotech?

    "The market is very favorable for biotech these days," says Les Funtleyder, Bluecloud Healthcare, in discussing growth in the space.

  • Biogen CEO: Want to stop inversions? Reform tax code

    CNBC's Meg Tirrell speaks to Dr. George Scangos, Biogen Idec CEO, about the company's Q2 earnings surge, drug pipeline, and America's tax code. Scangos says we need a corporate tax rate that is competitive with rest of the world and a territorial tax system.

  • Faber Report: Puma Biotech surges

    CNBC's David Faber reports Puma Biotechnology surges on positive results for a breast cancer drug.

  • Analyst calls out Yellen's biotech comments

    Mark Schoenbaum, ISI Group, explains why his views differ from Janet Yellen on whether the biotech sector is forming a bubble.

  • How will Yellen's comments impact US stocks?

    Dodge Dorland, Chairman & Chief Investment Officer at Landor & Fuest Capital Managers, says social media and biotech stocks may see more downside in the short run.